Recce Pharmaceuticals (ASX:RCE) secured clearance from an independent non-data safety review board to continue a phase 2 clinical trial evaluating the Recce 327 topical gel as a potential antibacterial product for acute skin infections, including diabetic foot infections, according to a Monday filing with the Australian bourse.
The disclosure follows a safety and efficacy review in which no serious adverse events were noted, the filing said.
Company shares fell almost 5% at market close on Monday.
Price (AUD): $0.48, Change: $-0.025, Percent Change: -4.95%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。